8-(2-fluoro-4-iodophenylamino)-5,5-dimethyl-5,6-dihydro-4H-9-thia-1,2,3a-triaza-cyclopenta[e]azulene-7-carboxylic acid ethyl ester | 1174459-34-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 8-(2-fluoro-4-iodophenylamino)-5,5-dimethyl-5,6-dihydro-4H-9-thia-1,2,3a-triaza-cyclopenta[e]azulene-7-carboxylic acid ethyl ester
• 英文别名: Ethyl 12-(2-fluoro-4-iodoanilino)-8,8-dimethyl-13-thia-3,4,6-triazatricyclo[8.3.0.02,6]trideca-1(10),2,4,11-tetraene-11-carboxylate
• CAS: 1174459-34-7
• 化学式: C₂₀H₂₀FIN₄O₂S
• 分子量: 526.373
• InChiKey: BISRTSZGUAMNDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  97.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  8-(2-fluoro-4-iodophenylamino)-5,5-dimethyl-5,6-dihydro-4H-9-thia-1,2,3a-triaza-cyclopenta[e]azulene-7-carboxylic acid ethyl ester 在 lithium hydroxide monohydrate 、 水 、 柠檬酸 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以84%的产率得到8-(2-fluoro-4-iodophenylamino)-5,5-dimethyl-5,6-dihydro-4H-9-thia-1,2,3a-triaza-cyclopenta[e]azulene-7-carboxylic acid
  参考文献：
  名称：

  [EN] FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS
  [FR] DÉRIVÉS DE THIOPHÈNE TRICYCLIQUE CONDENSÉS SERVANT D'INHIBITEURS DE MEK

  摘要：

  一系列在2-位置被取代苯胺基团取代的融合三环噻吩衍生物，作为选择性抑制人类MEK（MAPKK）酶的药物，在医学上具有益处，例如在治疗炎症、自身免疫、心血管、增殖（包括肿瘤学）和疼痛条件方面。

  公开号：

  WO2009093009A1
• 作为产物：
  描述：

  2-(2-fluoro-4-iodophenylamino)-8-hydrazono-5,5-dimethyl-5,6,7,8-tetrahydro-4H-thieno|[2,3-c]azepine-3-carboxylic acid ethyl ester 、 原甲酸三乙酯 反应 0.17h， 以25%的产率得到8-(2-fluoro-4-iodophenylamino)-5,5-dimethyl-5,6-dihydro-4H-9-thia-1,2,3a-triaza-cyclopenta[e]azulene-7-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS
  [FR] DÉRIVÉS DE THIOPHÈNE TRICYCLIQUE CONDENSÉS SERVANT D'INHIBITEURS DE MEK

  摘要：

  一系列在2-位置被取代苯胺基团取代的融合三环噻吩衍生物，作为选择性抑制人类MEK（MAPKK）酶的药物，在医学上具有益处，例如在治疗炎症、自身免疫、心血管、增殖（包括肿瘤学）和疼痛条件方面。

  公开号：

  WO2009093009A1

文献信息

• METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV

  公开号：US20150265679A1

  公开（公告）日：2015-09-24

  What is described is a method for treating an adverse side effect of MEK inhibitors by administering a pharmaceutical composition comprising IFNγ to a cancer patient being treated by a MEK-inhibitor. The applicants discovered that MEK inhibitors produce unwanted visual disturbances as an adverse side effect in a significant fraction of cancer patients being treated by the drug, and that the side effect causes retinal detachment due to fluid accumulation in the eye. The method treats the retinal detachment caused by the anticancer therapeutic by providing a means of decreasing the amount of fluid present in the retina and/or subretinal space of the eye by administering the pharmaceutical composition comprising IFNγ to the basolateral side of the retinal pigment epithelium, preferably by administering the pharmaceutical composition to the anterior surface of the eye in liquid droplets.